Design Therapeutics Stock Performance
| DSGN Stock | USD 3.53 0.02 0.57% |
The firm shows a Beta (market volatility) of 0.88, which means possible diversification benefits within a given portfolio. Design Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Design Therapeutics is expected to follow. At this point, Design Therapeutics has a negative expected return of -0.0498%. Please make sure to confirm Design Therapeutics' value at risk, as well as the relationship between the skewness and day median price , to decide if Design Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Design Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy technical and fundamental indicators, Design Therapeutics is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 4.46 | Five Day Return (1.13) | Year To Date Return (43.11) | Ten Year Return (91.54) | All Time Return (91.54) |
1 | Design Therapeutics to Participate in Leerinks Global Healthcare Conference | 03/03/2025 |
2 | Acquisition by William Arsani of 1960000 shares of Design Therapeutics at 2.44 subject to Rule 16b-3 | 03/05/2025 |
3 | Design Therapeutics Highlights Progress Across Lead GeneTAC Programs and Reports Fourth Quarter and Full Year 2024 Financial Results | 03/10/2025 |
4 | Design Therapeutics Upgraded to Buy Heres Why | 03/12/2025 |
5 | Disposition of 814874 shares by William Arsani of Design Therapeutics at 4.25 subject to Rule 16b-3 | 03/13/2025 |
6 | Acquisition by George Simeon of 936637 shares of Design Therapeutics subject to Rule 16b-3 | 03/21/2025 |
7 | Design Therapeutics Welcomes Chris Storgard as New Chief Medical Officer DSGN Stock News | 04/17/2025 |
8 | Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator Park City 2025 | 04/21/2025 |
9 | Design Therapeutics Reveals Positive Phase 1 Trial Results for DT-168 DSGN Stock News | 05/01/2025 |
10 | Cautious Optimism for Design Therapeutics Hold Rating Amid Promising Phase 1 Results and Extended Development Timeline - TipRanks | 05/05/2025 |
11 | Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference | 05/13/2025 |
| Begin Period Cash Flow | 21.2 M |
Design Therapeutics Relative Risk vs. Return Landscape
If you would invest 413.00 in Design Therapeutics on February 18, 2025 and sell it today you would lose (60.00) from holding Design Therapeutics or give up 14.53% of portfolio value over 90 days. Design Therapeutics is currently does not generate positive expected returns and assumes 6.2433% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than Design, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Design Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Design Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Design Therapeutics, and traders can use it to determine the average amount a Design Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.008
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | DSGN |
Estimated Market Risk
| 6.24 actual daily | 55 55% of assets are less volatile |
Expected Return
| -0.05 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Design Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Design Therapeutics by adding Design Therapeutics to a well-diversified portfolio.
Design Therapeutics Fundamentals Growth
Design Stock prices reflect investors' perceptions of the future prospects and financial health of Design Therapeutics, and Design Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Design Stock performance.
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.17 | ||||
| Current Valuation | (28.27 M) | ||||
| Shares Outstanding | 56.77 M | ||||
| Price To Book | 0.87 X | ||||
| Price To Sales | 22,642 X | ||||
| Gross Profit | (49.93 M) | ||||
| EBITDA | (48.99 M) | ||||
| Net Income | (49.59 M) | ||||
| Cash And Equivalents | 359.38 M | ||||
| Cash Per Share | 6.45 X | ||||
| Total Debt | 2.33 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 48.96 X | ||||
| Book Value Per Share | 4.01 X | ||||
| Cash Flow From Operations | (43.1 M) | ||||
| Earnings Per Share | (0.99) X | ||||
| Market Capitalization | 199.26 M | ||||
| Total Asset | 252.09 M | ||||
| Retained Earnings | (227.21 M) | ||||
| Working Capital | 239.58 M | ||||
About Design Therapeutics Performance
By examining Design Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Design Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Design Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -1 K | -954 | |
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.26) | (0.24) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.20) | (0.19) |
Things to note about Design Therapeutics performance evaluation
Checking the ongoing alerts about Design Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Design Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Design Therapeutics generated a negative expected return over the last 90 days | |
| Design Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (49.59 M) with loss before overhead, payroll, taxes, and interest of (49.93 M). | |
| Design Therapeutics currently holds about 359.38 M in cash with (43.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Design Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 61.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference |
- Analyzing Design Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Design Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Design Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Design Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Design Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Design Therapeutics' stock. These opinions can provide insight into Design Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Design Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Design Therapeutics. If investors know Design will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Design Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Design Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Design Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.